Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization

Summary

The purpose of this study is to determine whether Shexiang Baoxin Pill is effective in the treatment of coronary artery disease not amenable to revascularization on the basis of western medicine therapy.

Conditions

• Coronary Artery Disease(CAD)

Interventions

DRUG

Shexiang Baoxin pill

Conventional western medicine \& shexiang baoxin pill

DRUG

SBP placebo

Conventional western medicine \& placebo (for shexiang baoxin pill)

DRUG

Aspirin Enteric-coated Tablets

100mg tablet, one tablet daily.

DRUG

Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet

one tablet daily. (for patients who can't use aspirin)

DRUG

Atorvastatin Calcium

10 mg tablet, two tablets each night.

DRUG

Isosorbide Mononitrate Tab 20 MG

1 tablet two times daily.

DRUG

Metoprolol Tartrate Tab 25 MG

12.5 mg or 25 mg two times daily.

DRUG

Trimetazidine Dihydrochloride Tablets

20 mg tablet, one tablet three times daily.

Sponsors & Collaborators

• Shanghai Hutchison Pharmaceuticals Limited

  collaborator INDUSTRY

• Jun Li

  lead OTHER

Principal Investigators

• Jie Wang, MD · Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

45 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-06-30

Primary Completion

2018-12-31

Completion

2019-02-28